Journey Medical Corp DERM
We take great care to ensure that the data presented and summarized in this overview for Journey Medical Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DERM
View all-
Tang Capital Management LLC San Diego, CA1.85MShares$12.8 Million0.71% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT931KShares$6.42 Million0.03% of portfolio
-
B. Riley Securities, Inc. Los Angeles, CA865KShares$5.97 Million0.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA372KShares$2.57 Million0.0% of portfolio
-
Cambridge Investment Research Advisors, Inc.338KShares$2.33 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny238KShares$1.64 Million0.0% of portfolio
-
American Financial Group Inc180KShares$1.24 Million0.5% of portfolio
-
Pvg Asset Management Corp Golden, CO174KShares$1.2 Million4.83% of portfolio
-
Geode Capital Management, LLC Boston, MA114KShares$784,8120.0% of portfolio
-
Envestnet Asset Management Inc103KShares$711,7550.0% of portfolio
Latest Institutional Activity in DERM
Top Purchases
Top Sells
About DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Insider Transactions at DERM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 25
2025
|
Lindsay A Md Rosenwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,173
+4.26%
|
-
|
|
Jun 25
2025
|
Miranda Jayne Toledano Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,173
+7.49%
|
-
|
|
Jun 25
2025
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,173
+7.49%
|
-
|
|
Jun 25
2025
|
Justin Adam Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,173
+4.52%
|
-
|
|
Jun 25
2025
|
Michael Cooper Pearce Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,173
+16.18%
|
-
|
|
Jun 17
2025
|
Claude Maraoui President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
49,277
+2.01%
|
-
|
|
Jun 17
2025
|
Joseph Benesch CFO |
BUY
Grant, award, or other acquisition
|
Direct |
28,907
+11.06%
|
-
|
|
Jun 17
2025
|
Ramsey Alloush Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,863
+7.83%
|
-
|
|
May 02
2025
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
4,834
-0.21%
|
$29,004
$6.84 P/Share
|
|
May 02
2025
|
Ramsey Alloush Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,857
-0.56%
|
$17,142
$6.84 P/Share
|
|
May 02
2025
|
Joseph Benesch CFO |
SELL
Open market or private sale
|
Direct |
2,409
-1.17%
|
$14,454
$6.84 P/Share
|
|
Mar 11
2025
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
49,271
-2.4%
|
$246,355
$5.01 P/Share
|
|
Mar 07
2025
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
14,905
-0.72%
|
$74,525
$5.01 P/Share
|
|
Mar 06
2025
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
25,551
-1.22%
|
$127,755
$5.04 P/Share
|
|
Mar 05
2025
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
18,147
-0.86%
|
$90,735
$5.13 P/Share
|
|
Mar 04
2025
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
28,901
-1.35%
|
$144,505
$5.04 P/Share
|
|
Mar 03
2025
|
Claude Maraoui President & CEO |
SELL
Open market or private sale
|
Direct |
23,508
-1.09%
|
$117,540
$5.19 P/Share
|
|
Feb 21
2025
|
Joseph Benesch CFO |
SELL
Open market or private sale
|
Direct |
1,365
-2.88%
|
$6,825
$5.19 P/Share
|
|
Aug 01
2024
|
Joseph Benesch CFO |
SELL
Open market or private sale
|
Direct |
9,324
-16.46%
|
$46,620
$5.47 P/Share
|
|
Jul 23
2024
|
Joseph Benesch CFO |
SELL
Open market or private sale
|
Direct |
4,055
-6.68%
|
$20,275
$5.4 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 191K shares |
|---|
| Open market or private sale | 185K shares |
|---|